Study and baseline patient characteristics
| 1. Quantitative evidence | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Disease | Total Population No. | Women % | Age, mean (SD)/median (IQR), y | Disease duration, mean (SD)/median (IQR), year | Disease activity,* mean (SD) | MTX% | AZA/MCP % | CST % | Other IS % | No IS % | Biological | Posology |
| Objective 1 | |||||||||||||
| Wolbink 200612 | RA | 51 | 82 | 56† (13) | 12† (9) | 6.0 (1.3) | 86 | na | na | 8 | 6 | INF | Ind‡+3 mg/Kg q8w |
| Radstake 200919 | RA | 34 | 79 | 56† (10) | na | 5.7 (1.0) | 41 | na | 26 | 0 | 59 | ADL | 40 mg q2w |
| Radstake 200919 | RA | 35 | 86 | 57† (10) | na | 5.6 (1.2) | 100 | na | 29 | 0 | 0 | INF | Ind‡+3 mg/Kg q8w |
| Pascual-Salcedo 201114 | RA | 85 | 81 | 54† (14) | na | 5.5 (1.3) | 34 | na | 74 | 18 | 1 | INF | Ind‡+3 mg/Kg q8w |
| de Vries 20073 | AS | 38 | 31 | 40† (10) | na | 6.4 (1.2) | 0 | na | 8 | 16 | na | INF | Ind§+5 mg/Kg q6w |
| Hoffman 201126 | Ps | 29 | 45 | na | na | 14.7(10) | 24 | na | na | 7 | na | INF | Ind§+5 mg/Kg q8w |
| Objective 1 and 2 | |||||||||||||
| Bartelds 200720 | RA | 121 | 79 | 53† (13) | 12† (10) | 5.3 (1.1) | 79 | na | 34 | 12 | 20 | ADL | 40 mg q2w |
| Bender 200721 | RA | 15 | 67 | 56† (8.1) | 12† (8.2) | 6.5 (1.2) | 67 | 0 | 100 | 7 | 27 | INF | 40 mg q2w |
| Bartelds 20112 | RA | 272 | 81 | 54† (12) | 8¶ (3–17) | 5.2 (1.2) | 74 | na | 91 (33) | 19 (7) | 19 | ADL | 40 mg q2w |
| Lecluse 201025 | Ps | 29 | 31 | 44 (11) | 22 (na) | 15.5(na) | 10 | na | na | na | 0 | ADL | Ind**+40 mg q2w |
| West 200822 | CD | 30 | 77 | 36†† (21–73) | na | na | 13 | 5 (17) | 13 | 0 | 57 | ADL | Ind‡‡+40 mg q2w |
| Study | Disease | Total population no. | Female % | Age, mean (sd)/median (IQR), year | Disease duration mean (sd)/median (IQR), y | Disease activity,* mean (SD) | MTX % | AZA/MCP % | CST % | Other IS % | No IS % | Biologic | Scheme |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Quantitative evidence | |||||||||||||
| Objective 1 and 2 | |||||||||||||
| Steenholdt 201123 | CD/UC | 106 | 54 | 30–41§§ | 3–10§§ | na | 7 | 62 | 1 | 20 (19) | na | INF | Ind§+5 mg/Kg q4–12w |
| Plasencia 201224 | SpA | 94 | 44 | 50 (11) | na | 3.1 (1.3) | 22 | na | 42 | 27 | 23 | INF | Ind§+5 mg/Kg q6w |
| Objective 2 | |||||||||||||
| Baert 20034 | CD | 125 | 66 | 35†† (17–73) | na | 260†† (0–575) | 2 | 45 | 42 | na | 14 | INF | 5 mg/Kg SD or Ind§+5 mg/Kg OD |
| Vermiere 200732 | CD | 174 | 61 | 39†† (18–73) | na | na | 29 | 37 | na | 0 | 34 | INF | 5 mg/Kg SD or Ind§+5 mg/Kg OD |
| Afif 200933 | CD/UC | 155 | 55 | 39†† (26–50) | 14¶ (na) | na | 8 | 37 | 10 | 0 | 42 | INF | 5 mg/Kg SD or Ind§+5 mg/Kgq8w |
| Maini 199835 | RA | 29 | 72 | 51† (na) | 10† (na) | 6.7 | 52 | 0 | 55 | 0 | 0 | INF | Ind‡+3 mg/Kg q4w |
| Bartelds 201034 | RA | 235 | 79 | 53† (12) | 9¶ (4–17) | 5.2 (1.2) | 82 | na | 34 | na | na | ADL | 40 mg q2w |
| 2. Qualitative evidence | |||||||||||||
| Objective 1 | |||||||||||||
| Van Kuijk 201028 | PsA | 22 | 36 | 43†† (21–61) | 6¶ (1–18) | 4.9¶¶ (0.3) | 55 | na | na | na | na | ADA | 40 mg q2w |
| Adisen 201031 | Ps | 15 | 47 | 38–74§§ | 30–40§§ | 11–36§§ | na | na | 27 | na | na | INF | Ind§+5 mg/Kg q8w |
| Jamnitski 201229 | RA | 292 | 82 | 53† (13) | 8¶ (3–16) | 5.2 (1.3) | 76 | na | 28 | 36 | na | ETA | 25 mg biw or 50 mg qw |
| Hoshino 201230 | RA | 40 | 88 | 60.5¶ (23–80) | 6.5¶ (1–45) | 5.4 (3.1–8.1) | 58 | 0 | 85 | 18 | 0 | ETA | 25 mg biw |
| De Vries 200927 | AS | 53 | 25 | 41† (11) | na | 6.4 (1.3) | na | na | na | na | na | ETA | 25 mg biw or 50 mg qw |
*DAS28 for RA and PsA patients, ASAS 20 or ASDAS for SpA and AS patients, PASI for Ps patients.
†Mean (SD).
‡Induction dose of 3 mg/kg at 0, 2 and 6 weeks.
§Induction dose of 5 mg/kg at 0, 2 and 6 weeks.
¶Median (range/IQR).
**Induction dose of 80 mg at wk 0 and 40 mg at wk 2.
††Mean (range/IQR).
‡‡Induction dose of 160 mg at wk 0 and 80 mg at wk 2.
§§Range.
¶¶Mean (SEM).
ADA, anti-drug antibodies; ADL, Adalimumab s.c.; AS, Ankylosing Spondylitis; ASAS, Ankylosing Spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; AZA, Azathioprine; biw, twice a week; CD, Crohn's Disease; CST, Corticosteroids; ETA, Etanercept s.c; INF, Infliximab i.v.; IS, Immunosuppression; MCP, 6-Mercaptopurine; MTX, Methotrexate; na, not available; OD, on demand; PASI, Psoriasis Area and Severity Index; Ps, Psoriasis; PsA, Psoriatic Arthritis; qw, every week; qXw, every X weeks; RA, Rheumatoid Arthritis; SD, single dose; SpA, Spondyloarthritis; UC, Ulcerative Colitis; wk, weeks.